RESULTS
The investigators at the six contributing centers monitored 39 HIV-infected women, each of whom Neonatal outcome data from the 39 pregnancies are summarized in Table 4 . No clinical d7smor- Through collaborative compilation of data from six perinatal centers, we have been able to present a preliminary experience with the use of combination nucleoside analog therapy during pregnancy. These outcomes predate the inclusion of protease inhibitors in most adult combination regimens and reflect the intent of the investigators to augment maternal therapy by using additional medications from a class for which neonatal exposure and safety profiles had at least been previously described. 4, 16, 7 For the most part, lamivudine was the second agent of choice, since its acceptability to patients in terms of dosing and side effects had been well-described in other adult groups, 
